Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDLigand Pharmaceuticals Incorporated Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 2 | $1.08 | $1.36 | $1.21 |
| Q2 2025 | 7 | $1.27 | $1.73 | $1.42 |
| Q3 2025 | 4 | $1.82 | $2.10 | $1.93 |
| Q4 2025 | 5 | $1.17 | $1.97 | $1.54 |
| Q1 2026 | 1 | $1.37 | $1.72 | $1.54 |
| Q2 2026 | 1 | $1.51 | $1.90 | $1.70 |
| Q3 2026 | 1 | $1.96 | $2.48 | $2.21 |
| Q4 2026 | 1 | $2.00 | $2.52 | $2.25 |
Ligand Pharmaceuticals Incorporated Earnings Date And Information
Ligand Pharmaceuticals Incorporated last posted its earnings results on Thursday, November 6th, 2025. The company reported $3.09 earnings per share for the quarter, topping analysts' consensus estimates of $1.97 by $1.12. The company had revenue of 115.46 M for the quarter and had revenue of 167.13 M for the year. Ligand Pharmaceuticals Incorporated has generated $0 earnings per share over the last year ($-0.22 diluted earnings per share) and currently has a price-to-earnings ratio of 101.08. Ligand Pharmaceuticals Incorporated has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based on prior year's report dates.
Ligand Pharmaceuticals Incorporated Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2025 | Q3 2025 | N/A | $5.99 | N/A | $58.74 M | $115.46 M |
| 08/08/2025 | Q2 2025 | N/A | $0.25 | N/A | $43.87 M | $47.63 M |
| 05/09/2025 | Q1 2025 | N/A | -$2.21 | N/A | N/A | $45.33 M |
| 02/28/2025 | Q4 2024 | N/A | -$1.64 | N/A | N/A | $42.81 M |
| 11/08/2024 | Q3 2024 | N/A | -$0.39 | N/A | $40.60 M | $51.81 M |
| 08/07/2024 | Q2 2024 | N/A | -$2.88 | N/A | $33.04 M | $41.53 M |
| 05/08/2024 | Q1 2024 | N/A | $4.86 | N/A | N/A | $30.98 M |
| 02/29/2024 | Q4 2023 | N/A | $1.04 | N/A | N/A | $28.10 M |
| 11/09/2023 | Q3 2023 | N/A | -$0.74 | N/A | $27.22 M | $32.87 M |
| 08/09/2023 | Q2 2023 | N/A | $0.13 | N/A | $24.74 M | $26.37 M |
| 05/08/2023 | Q1 2023 | N/A | $2.46 | N/A | $33.55 M | $43.98 M |
| 02/28/2023 | Q4 2022 | N/A | -$1.04 | N/A | $44.09 M | $27.05 M |
| 11/08/2022 | Q3 2022 | N/A | $0.02 | N/A | $38.32 M | $59.22 M |
| 08/09/2022 | Q2 2022 | N/A | -$0.05 | N/A | $37.73 M | $50.13 M |
| 05/09/2022 | Q1 2022 | N/A | -$0.91 | N/A | $34.21 M | $36.52 M |
| 02/28/2022 | Q4 2021 | N/A | -$0.30 | N/A | $65.09 M | $72.47 M |
| 11/09/2021 | Q3 2021 | $1.02 | $0.82 | -0.2 | $58.74 M | $64.84 M |
| 08/02/2021 | Q2 2021 | N/A | $1.84 | N/A | $71.41 M | $84.68 M |
| 05/06/2021 | Q1 2021 | N/A | $1.10 | N/A | $62.91 M | $55.15 M |
| 02/24/2021 | Q4 2020 | N/A | $0.36 | N/A | $56.68 M | $69.99 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Ligand Pharmaceuticals Incorporated Earnings: FAQ's
Ligand Pharmaceuticals Incorporated has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, November 6th, 2025 based offlast year's report dates.
In the previous quarter, Ligand Pharmaceuticals Incorporated (:LGND) reported $3.09 earnings per share (EPS) to beat the analysts' consensus estimate of $1.97 by $1.12.
The conference call for Ligand Pharmaceuticals Incorporated's latest earnings report can be listened to online.
The conference call transcript for Ligand Pharmaceuticals Incorporated's latest earnings report can be read online.
Ligand Pharmaceuticals Incorporated (:LGND) has a recorded annual revenue of $167.13 M.
Ligand Pharmaceuticals Incorporated (:LGND) has a recorded net income of $-4,032,000.Ligand Pharmaceuticals Incorporated has generated $-0.22 earnings per share over the last four quarters.
Ligand Pharmaceuticals Incorporated (:LGND) has a price-to-earnings ratio of 101.08 and price/earnings-to-growth ratio is 0.62.